Cardiovascular medicine – BJC TV

Heart failure in black patients – exploring genes and cardiac amyloidosis

hginn@omniamed.com — Wed, 22 Jul 2026 16:12:45 +0000

Learning objectives:

To understand the difference between Transthyretin Amyloidosis (ATTR) and Amyloid Light-chain Amyloidosis (AL)
To learn about the hereditary subtype ATTR V122I and how it affects patients of black ethnicity
To develop an understanding of the challenges faced in diagnosing and treating this condition
To gain awareness of ways to support black patients with hereditary ATTR and those who carry the gene
To feel empowered to diagnose ATTR and develop a knowledge of the condition to implement in clinical practise in a culturally sensitive way.

Speaker

Dr Jason Dungu PhD, FRCP, FESC

Consultant Cardiologist and Essex ICC Lead, Essex Cardiothoracic Centre, Mid & South Essex NHS Foundation Trust Honorary Senior Clinical Lecturer, Anglia Ruskin University

BEACON series – Episode 4: Type 2 diabetes and chronic kidney disease

jleiwy@omniamed.com — Mon, 13 Jul 2026 08:21:00 +0000

In this interactive BEACON session, the faculty explore the complexities of managing multifactorial cardiometabolic risk in primary care, looking at a 67-year-old man with long-standing type 2 diabetes, CKD stage 3a with rising albuminuria, obesity and multiple modifiable risk factors.

BEACON series – Episode 3: CVD risk management in type 2 diabetes

jleiwy@omniamed.com — Mon, 13 Jul 2026 08:20:35 +0000

In this interactive BEACON session, the faculty explore the management of cardiovascular risk in people with type 2 diabetes. They examine how to optimise lipid-lowering therapy, blood pressure control and glucose management, alongside addressing renal risk and implementing evidence-based interventions to reduce long-term cardiovascular complications.

BEACON series – Episode 2: Secondary prevention post-MI and peripheral artery disease

jleiwy@omniamed.com — Mon, 13 Jul 2026 08:20:09 +0000

This interactive BEACON session explores the optimisation of secondary cardiovascular prevention in patients with established atherosclerotic cardiovascular disease. Herein, the faculty will examine how to identify and address residual cardiovascular risk, optimise lipid-lowering therapy beyond statins, and implement evidence-based strategies to achieve recommended LDL-C targets.

BEACON series – Episode 1: Primary prevention of CVD – QRISK® <10%

jleiwy@omniamed.com — Mon, 13 Jul 2026 08:12:36 +0000

This interactive BEACON session explores the management of younger patients at high lifetime cardiovascular risk whose QRISK® scores may underestimate their true risk. The faculty will examine how to identify patients who would benefit from earlier intervention, interpret lifetime versus 10-year cardiovascular risk, and optimise lipid-lowering and cardiovascular risk reduction strategies in line with current evidence and guidelines.

Key differences between Kerendia▼ (finerenone) and steroidal MRAs

jleiwy@omniamed.com — Fri, 19 Jun 2026 14:01:00 +0000

Prescribing information and adverse event reporting information for Kerendia^®▼(finerenone) can be found here.

Featuring

Professor John McMurray, Professor of Cardiology (Cardiology & Metabolic Health), School of Cardiovascular and Metabolic Health
Professor Richard Hobbs, Mercian Professor of Primary Care, University of Oxford

References

Piccirillo F, Liporace P, Nusca A et al. Effects of finerenone on cardiovascular and chronic kidney diseases: a new weapon against cardiorenal morbidity and mortality‑a comprehensive review. J Cardiovasc Dev Dis 2023;10:236.
Kolkhof P, Jaisser F, Kim S-Y et al. Steroidal and novel non‑steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: comparison at bench and bedside. In Bauersachs J et al (eds): Heart failure. Springer International Publishing, Cham, Switzerland, 2017:271–305.
Spironolactone Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/12015/smpc#gref.
Eplerenone Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/8810/smpc.

DOWNLOAD OUR DOSING GUIDE

Exercise in cardiomyopathy: What happens after the consultation?

hginn@omniamed.com — Fri, 29 May 2026 10:18:16 +0000

Learning objectives:

To understand that exercise is possible for nearly all cardiomyopathy patients
To learn successful ways to tailor exercise for individual patients
To develop an understanding of the ACTIVE clinical approach and the four pillars of cardiovascular rehabilitation
To gain awareness of how to support patients safely with practical exercise prescription
To feel inspired to help patients manage their cardiovascular health with confidence

Speaker: Shane Purcell Clinical Exercise Physiologist, Imperial College Healthcare NHS Trust

Insights from the ESC Heart Failure Congress, 2026

jtaylor@omniamed.com — Fri, 15 May 2026 14:02:25 +0000

Learn more about some of the key sessions from the conference:

Cardiac amyloidosis: early diagnosis matters

Controversies in contemporary drug therapy for heart failure

How to crack the cardiorenal code: from clinical mastery to unit creation

Advances in cardiomyopathies

Debate: artificial intelligence in heart failure care, a great equaliser or a new divider?

Speaker

Dr Sarah Birkhoelzer, Heart Failure and Imaging Fellow, University Hospital Dorset

Living and dying well with heart failure – how can palliative care help?

jtaylor@omniamed.com — Wed, 06 May 2026 09:35:23 +0000

Learning objectives:

To understand the potential role of palliative care in supporting heart failure patients
To learn about down titrating some medications to improve symptom control and reduce side effects
To develop an understanding of advance care planning including DNACPR & ICD deactivation
To gain awareness of the ethical dilemmas that might arise
To feel inspired to develop relationships with your local palliative care providers and work together more closely

Speaker

Dr Sharon Chadwick, Consultant in Palliative Medicine, Hospice of St Francis, Berkhamsted, Hertfordshire

Exploring cardiac amyloidosis: Diagnosis, treatment, and best practices

jleiwy@omniamed.com — Tue, 31 Mar 2026 14:18:46 +0000

Studies report up to 18% (n/N = 9/49) of patients aged ≥60 years old with heart failure with preserved ejection fraction (HFpEF) had transthyretin amyloid cardiomyopathy (ATTR-CM), one of the main types of cardiac amyloidosis.¹ Clinical expert Dr Kate Gatenby highlights this and gives an overview of the causes, diagnosis and best practices in the management of patients with ATTR-CM.